Luminopia, a Cambridge, MA-based prescription digital therapeutics company, raised $5.7M in Seed Extension funding.
The round was led by ShangBay Capital, with participation from Sony Innovation Fund, The Vertical Group, and SSI Strateg. With the closing of the round, William Dai, Founding Managing Partner of ShangBay Capital, will be joining Luminopia’s Board of Directors.
The company intends to us the funds for a staged rollout of its lead product for amblyopia to pediatric ophthalmologists starting this month, before expanding to a broader launch in the second half of 2023.
Led by CEO Scott Xiao, Luminopia provides treatments for significant neuro-visual disorders. The company is committed to creating digital therapeutics that are both rigorously evaluated for FDA approval and genuinely engaging for patients. As an Innovation Partner of Boston Children’s Hospital, Luminopia is developing its lead product to improve vision in children with amblyopia, the leading cause of vision loss among children.
The therapeutic is a clinically validated digital therapy to improve vision in children with amblyopia (lazy eye), the leading cause of vision loss among children, and was approved by the U.S. Food and Drug Administration (FDA) through the De Novo pathway in October 2021. Upon launch, the therapeutic will be prescribed by eye care professionals and distributed through an online retail pharmacy.
FinSMEs
14/11/2022